|Day Low/High||27.39 / 28.26|
|52 Wk Low/High||18.52 / 45.90|
Startups to Utilize ActoBiotics™ Platform to Develop Innovative Treatments for Celiac Disease and Chronic Rhinosinusitis
Demand is quite healthy and markets are not going into the abyss, Cramer says.
Publications in Journal of Clinical Investigation demonstrate potential of ExeGen® CFTR models
Florida officials are pressing the government to authorize emergency use of Intrexon's (XON) genetically modified mosquitoes to combat the Zika virus.
Florida politicians issued a letter Wednesday urging the federal government to allow the state to use genetically engineered mosquitos made by Intrexon's (XON) Oxitec unit to fight the Zika virus.
Where some see danger and upheaval, investors see opportunity. And the harrowing Zika virus is no different. Investors are jumping into stocks focused on detecting or wiping out the virus.
The most recent short interest data was recently released for the 08/15/2016 settlement date, and Intrexon Corp is one of the most shorted stocks of the Russell 3000, based on 9.06 "days to cover" versus the median component at 5.83. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.
In trading on Monday, shares of Intrexon Corp crossed above their 200 day moving average of $30.42, changing hands as high as $30.56 per share. Intrexon Corp shares are currently trading up about 3.5% on the day.
This market is like a leaky helium balloon; watch out for sudden downdrafts.
Trade-Ideas LLC identified Intrexon (XON) as a weak on high relative volume candidate
Genetic "On-Off" Switch Promises Broad, Innovative Applications in Agriculture
MIT's Smart 50 list recognizes companies for their combination of innovative technology and effective management, and it includes 13 pharmaceutical and biotech firms this year.
Trade-Ideas LLC identified Intrexon (XON) as a "dead cat bounce" (down big yesterday but up big today) candidate
Expanded project begins Tuesday July 19th; Sao Judas is the first central neighbourhood to receive the mosquito that fights the primary vector of dengue, Zika and chikungunya
The circumstances surrounding the Ziopharm patient deaths come amid heightened scrutiny of experimental anti-cancer therapies.
The amended agreement with Intrexon bolsters the bear argument against Ziopharm that its entire cancer drug pipeline is mediocre and overvalued.
Trade-Ideas LLC identified Intrexon (XON) as a "perilous reversal" (up big yesterday but down big today) candidate